Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Income (2016 - 2025)

ImmunityBio (IBRX) has disclosed Non Operating Income for 12 consecutive years, with $96.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 238.25% to $96.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.3 million through Dec 2025, up 157.4% year-over-year, with the annual reading at -$2.2 million for FY2025, 96.87% up from the prior year.
  • Non Operating Income for Q4 2025 was $96.0 million at ImmunityBio, up from -$11.7 million in the prior quarter.
  • The five-year high for Non Operating Income was $96.0 million in Q4 2025, with the low at -$69.4 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$6.5 million, with a median of -$4.2 million recorded in 2021.
  • The sharpest move saw Non Operating Income soared 3344.24% in 2021, then plummeted 97700.0% in 2024.
  • Over 5 years, Non Operating Income stood at $7.5 million in 2021, then crashed by 112.35% to -$923000.0 in 2022, then skyrocketed by 92.31% to -$71000.0 in 2023, then tumbled by 97700.0% to -$69.4 million in 2024, then skyrocketed by 238.25% to $96.0 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $96.0 million, -$11.7 million, and -$21.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.